Treatment of type 2 diabetes mellitus via reversing insulin resistance and regulating lipid homeostasis in vitro and in vivo using cajanonic acid A

Yang,Ruiyi; Wang,Lu; Xie,Jie; Li,Xiang; Liu,Shan; Qiu,Shengxiang; Hu,Yingjie; Shen,Xiaoling

doi:10.3892/ijmm.2018.3836

Treatment of type 2 diabetes mellitus via reversing insulin resistance and regulating lipid homeostasis in vitro and in vivo using cajanonic acid A

Authors:
- Ruiyi Yang
- Lu Wang
- Jie Xie
- Xiang Li
- Shan Liu
- Shengxiang Qiu
- Yingjie Hu
- Xiaoling Shen
View Affiliations

Affiliations: Laboratory of Chinese Herbal Drug Discovery, Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, P.R. China, Key Laboratory of Plant Resources Conservation and Sustainable Utilization, South China Botanical Garden, Chinese Academy of Sciences, Guangzhou, Guangdong 510650, P.R. China
Published online on: August 23, 2018 https://doi.org/10.3892/ijmm.2018.3836
Pages: 2329-2342
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the effects of cajanonic acid A (CAA), extracted from the leaves of Cajanus cajan (L.) Millsp with a purity of 98.22%, on the regulatory mechanisms of glucose and lipid metabolism. HepG2 cells transfected with a protein‑tyrosine phosphatase 1B (PTP1B) overexpression plasmid were established. The cells, induced with insulin resistance by dexamethasone (Dex) treatment, together with type 2 diabetes mellitus (T2DM) model rats and ob/ob mice, were used in the present study. The effects of CAA treatment on the differentiation of 3T3‑L1 adipocytes were determined using Oil Red O. The expression levels of insulin signaling factors were detected via reverse transcription‑quantitative polymerase chain reaction and western blot analyses. The results revealed that the overexpression of PTP1B contributed to insulin resistance, which was reversed by CAA treatment via inhibiting the activity of PTP1B and by regulating the expression of associated insulin signaling factors. The treatment of cell lines with Dex led to increased expression of PTP1B but decreased glucose consumption, and decreased tyrosine phosphorylation of insulin receptor, insulin receptor substrate 1, and phosphoinositide 3‑kinase. Treatment with CAA not only reduced the fasting blood glucose levels and protected organs from damage, but also reduced the serum fasting levels of total cholesterol, triglycerides and low‑density lipoprotein cholesterol in the T2DM rats. CAA treatment also inhibited adipocyte differentiation and decreased the mRNA levels of various adipogenic genes. Furthermore, CAA treatment restored the transduction of insulin signaling by regulating the expression of PTP1B and associated insulin signaling factors. Treatment with CAA also reduced the problems associated with hyperglycemia and hyperlipidemia. In conclusion, CAA may be used to cure T2DM via restoring insulin resistance and preventing obesity.

View Figures

View References

1	Kahn BB: Type 2 diabetes: When insulin secretion fails to compensate for insulin resistance. Cell. 92:593–596. 1998. View Article : Google Scholar : PubMed/NCBI
2	Kahn SE, Hull RL and Utzschneider KM: Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 444:840–846. 2006. View Article : Google Scholar : PubMed/NCBI
3	Mayer-Davis EJ, D'Agostino R Jr, Karter AJ, Haffner SM, Rewers MJ, Saad M and Bergman RN: Intensity and amount of physical activity in relation to insulin sensitivity: The insulin resistance atherosclerosis study. JAMA. 279:669–674. 1998. View Article : Google Scholar : PubMed/NCBI
4	Kaur J: A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014:9431622014. View Article : Google Scholar : PubMed/NCBI
5	Ma YM, Tao RY, Liu Q, Li J, Tian JY, Zhang XL, Xiao ZY and Ye F: PTP1B inhibitor improves both insulin resistance and lipid abnormalities in vivo and in vitro. Mol Cell Biochem. 357:65–72. 2011. View Article : Google Scholar : PubMed/NCBI
6	Seely BL, Staubs PA, Reichart DR, Berhanu P, Milarski KL, Saltiel AR, Kusari J and Olefsky JM: Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes. 45:1379–1385. 1996. View Article : Google Scholar : PubMed/NCBI
7	Knobler H and Elson A: Metabolic regulation by protein tyrosine phosphatases. J Biomed Res. 28:157–168. 2014.PubMed/NCBI
8	Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC, et al: Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 283:1544–1548. 1999. View Article : Google Scholar : PubMed/NCBI
9	Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kim YB, Sharpe A, et al: Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol. 20:5479–5489. 2000. View Article : Google Scholar : PubMed/NCBI
10	Koren S and Fantus IG: Inhibition of the protein tyrosine phosphatase PTP1B: Potential therapy for obesity, insulin resistance and type-2 diabetes mellitus. Best Pract Res Clin Endocrinol Metab. 21:621–640. 2007. View Article : Google Scholar : PubMed/NCBI
11	Sun C, Zhang F, Ge X, Yan T, Chen X, Shi X and Zhai Q: SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 6:307–319. 2007. View Article : Google Scholar : PubMed/NCBI
12	Obanda DN and Cefalu WT: Modulation of cellular insulin signaling and PTP1B effects by lipid metabolites in skeletal muscle cells. J Nutr Biochem. 24:1529–1537. 2013. View Article : Google Scholar : PubMed/NCBI
13	Qiu SX and Shen XL: A hypoglycemic and slimming stilbenoidal natureal medicine. CN Patent 101422450. Filed October 9, 2008; issued May 6, 2009.
14	Cai JZ, Tang R, Ye GF, Qiu SX, Zhang NL, Hu YJ and Shen XL: A Halogen-containing stilbene derivative from the leaves of Cajanus cajan that induces osteogenic differentiation of human mesenchymal stem cells. Molecules. 20:10839–10847. 2015. View Article : Google Scholar : PubMed/NCBI
15	Yuan J, Lin J, Xu C, Ye Q, Xiong Y, Huang L and Yuan H: Experimental research on prevention of glucocorticoid-induced avascular necrosis of the femoral head with tongluo shenggu capsule. Tradit Chin Drug Res Clin Pharmacol. 16:185–188. 2005.In Chinese.
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
17	Samuel VT, Petersen KF and Shulman GI: Lipid-induced insulin resistance: Unravelling the mechanism. Lancet. 375:2267–2277. 2010. View Article : Google Scholar : PubMed/NCBI
18	Nandi A, Kitamura Y, Kahn CR and Accili D: Mouse models of insulin resistance. Physiol Rev. 84:623–647. 2004. View Article : Google Scholar : PubMed/NCBI
19	Duque-Guimaraes DE and Ozanne SE: Nutritional programming of insulin resistance: Causes and consequences. Trends Endocrinol Metab. 24:525–535. 2013. View Article : Google Scholar : PubMed/NCBI
20	Krook A, Wallberg-Henriksson H and Zierath JR: Sending the signal: molecular mechanisms regulating glucose uptake. Med Sci Sports Exerc. 36:1212–1217. 2004. View Article : Google Scholar : PubMed/NCBI
21	Huang S and Czech MP: The GLUT4 glucose transporter. Cell Metab. 5:237–252. 2007. View Article : Google Scholar : PubMed/NCBI
22	Lochhead P, Coghlan M, Rice S and Sutherland C: Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression. Diabetes. 50:937–946. 2001. View Article : Google Scholar : PubMed/NCBI
23	Chi YJ, Li J, Guan YF and Yang JC: PI3K/Akt signaling axis in regulation of glucose homeostasis. Chin J Biochem Mol Biol. 26:879–885. 2010.In Chinese.
24	Bhattacharya S, Dey D and Roy SS: Molecular mechanism of insulin resistance. J Biosci. 32:405–413. 2002. View Article : Google Scholar
25	Delibegovic M, Zimmer D, Kauffman C, Rak K, Hong EG, Cho YR, Kim JK, Kahn BB, Neel BG and Bence KK: Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes. 58:590–599. 2009. View Article : Google Scholar :
26	López-Terrada D, Cheung SW, Finegold MJ and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum Pathol. 40:1512–1515. 2009. View Article : Google Scholar : PubMed/NCBI
27	Cheng A, Uetani N, Simoncic PD, Chaubey VP, Lee-Loy A, McGlade CJ, Kennedy BP and Tremblay ML: Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell. 2:497–503. 2002. View Article : Google Scholar
28	Bence KK, Delibegovic M, Xue B, Gorgun CZ, Hotamisligil GS, Neel BG and Kahn BB: Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med. 12:917–924. 2006. View Article : Google Scholar : PubMed/NCBI
29	Goldstein BJ: Regulation of insulin receptor signaling by protein-tyrosine dephosphorylation. Receptor. 3:1–15. 1993.PubMed/NCBI
30	Lee JE and Ge K: Transcriptional and epigenetic regulation of PPARγ expression during adipogenesis. Cell Biosci. 4:1–11. 2014. View Article : Google Scholar
31	Song DD, Chen Y, Li ZY, Guan YF, Zou DJ and Miao CY: Protein tyrosine phosphatase 1B inhibits adipocyte differentiation and mediates TNFα action in obesity. Biochim Biophys Acta. 1831:1368–1376. 2013. View Article : Google Scholar : PubMed/NCBI
32	Gregoire FM, Smas CM and Sul HS: Understanding adipocyte differentiation. Physiol Rev. 78:783–809. 1998. View Article : Google Scholar : PubMed/NCBI